Global PET Radiopharmaceuticals Market Size, Share, Trends and Forecast 2020-2026

Description

The global PET Radiopharmaceuticals market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
This report focuses on PET Radiopharmaceuticals volume and value at the global level, regional level and company level. From a global perspective, this report represents overall PET Radiopharmaceuticals market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, etc.
Global PET Radiopharmaceuticals Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Global PET Radiopharmaceuticals Market: Regional Analysis
The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.
Global PET Radiopharmaceuticals Market: Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
Following are the segments covered by the report are:
F-18
Ru-82
Others
By Application:
Oncology
Cardiology
Neurology
Others
Key Players:
The Key manufacturers that are operating in the global PET Radiopharmaceuticals market are:
Cardinal Health Inc. (U.S.)
Mallinckrodt plc (Ireland)
GE Healthcare (U.K.)
Lantheus Medical Imaging, Inc. (U.S.)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Eczacibasi-Monrol Nuclear Products (Turkey)
Nordion, Inc. (Canada)
Advanced Accelerator Applications S.A. (France)
IBA Molecular Imaging (Belgium)
Competitive Landscape
The analysts have provided a comprehensive analysis of the competitive landscape of the global PET Radiopharmaceuticals market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

TABLE OF CONTENT

1 PET Radiopharmaceuticals Market Overview
1.1 Product Overview and Scope of PET Radiopharmaceuticals
1.2 PET Radiopharmaceuticals Segment by Type
1.2.1 Global PET Radiopharmaceuticals Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 F-18
1.2.3 Ru-82
1.2.4 Others
1.3 PET Radiopharmaceuticals Segment by Application
1.3.1 PET Radiopharmaceuticals Sales Comparison by Application: 2020 VS 2026
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Others
1.4 Global PET Radiopharmaceuticals Market Size Estimates and Forecasts
1.4.1 Global PET Radiopharmaceuticals Revenue 2015-2026
1.4.2 Global PET Radiopharmaceuticals Sales 2015-2026
1.4.3 PET Radiopharmaceuticals Market Size by Region: 2020 Versus 2026
1.5 PET Radiopharmaceuticals Industry
1.6 PET Radiopharmaceuticals Market Trends

2 Global PET Radiopharmaceuticals Market Competition by Manufacturers
2.1 Global PET Radiopharmaceuticals Sales Market Share by Manufacturers (2015-2020)
2.2 Global PET Radiopharmaceuticals Revenue Share by Manufacturers (2015-2020)
2.3 Global PET Radiopharmaceuticals Average Price by Manufacturers (2015-2020)
2.4 Manufacturers PET Radiopharmaceuticals Manufacturing Sites, Area Served, Product Type
2.5 PET Radiopharmaceuticals Market Competitive Situation and Trends
2.5.1 PET Radiopharmaceuticals Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key PET Radiopharmaceuticals Players (Opinion Leaders)

3 PET Radiopharmaceuticals Retrospective Market Scenario by Region
3.1 Global PET Radiopharmaceuticals Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global PET Radiopharmaceuticals Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America PET Radiopharmaceuticals Market Facts & Figures by Country
3.3.1 North America PET Radiopharmaceuticals Sales by Country
3.3.2 North America PET Radiopharmaceuticals Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe PET Radiopharmaceuticals Market Facts & Figures by Country
3.4.1 Europe PET Radiopharmaceuticals Sales by Country
3.4.2 Europe PET Radiopharmaceuticals Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific PET Radiopharmaceuticals Market Facts & Figures by Region
3.5.1 Asia Pacific PET Radiopharmaceuticals Sales by Region
3.5.2 Asia Pacific PET Radiopharmaceuticals Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America PET Radiopharmaceuticals Market Facts & Figures by Country
3.6.1 Latin America PET Radiopharmaceuticals Sales by Country
3.6.2 Latin America PET Radiopharmaceuticals Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa PET Radiopharmaceuticals Market Facts & Figures by Country
3.7.1 Middle East and Africa PET Radiopharmaceuticals Sales by Country
3.7.2 Middle East and Africa PET Radiopharmaceuticals Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global PET Radiopharmaceuticals Historic Market Analysis by Type
4.1 Global PET Radiopharmaceuticals Sales Market Share by Type (2015-2020)
4.2 Global PET Radiopharmaceuticals Revenue Market Share by Type (2015-2020)
4.3 Global PET Radiopharmaceuticals Price Market Share by Type (2015-2020)
4.4 Global PET Radiopharmaceuticals Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global PET Radiopharmaceuticals Historic Market Analysis by Application
5.1 Global PET Radiopharmaceuticals Sales Market Share by Application (2015-2020)
5.2 Global PET Radiopharmaceuticals Revenue Market Share by Application (2015-2020)
5.3 Global PET Radiopharmaceuticals Price by Application (2015-2020)

6 Company Profiles and Key Figures in PET Radiopharmaceuticals Business
6.1 Cardinal Health Inc. (U.S.)
6.1.1 Corporation Information
6.1.2 Cardinal Health Inc. (U.S.) Description, Business Overview and Total Revenue
6.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Cardinal Health Inc. (U.S.) Products Offered
6.1.5 Cardinal Health Inc. (U.S.) Recent Development
6.2 Mallinckrodt plc (Ireland)
6.2.1 Mallinckrodt plc (Ireland) Corporation Information
6.2.2 Mallinckrodt plc (Ireland) Description, Business Overview and Total Revenue
6.2.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Mallinckrodt plc (Ireland) Products Offered
6.2.5 Mallinckrodt plc (Ireland) Recent Development
6.3 GE Healthcare (U.K.)
6.3.1 GE Healthcare (U.K.) Corporation Information
6.3.2 GE Healthcare (U.K.) Description, Business Overview and Total Revenue
6.3.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.3.4 GE Healthcare (U.K.) Products Offered
6.3.5 GE Healthcare (U.K.) Recent Development
6.4 Lantheus Medical Imaging, Inc. (U.S.)
6.4.1 Lantheus Medical Imaging, Inc. (U.S.) Corporation Information
6.4.2 Lantheus Medical Imaging, Inc. (U.S.) Description, Business Overview and Total Revenue
6.4.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Lantheus Medical Imaging, Inc. (U.S.) Products Offered
6.4.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Development
6.5 Bayer AG (Germany)
6.5.1 Bayer AG (Germany) Corporation Information
6.5.2 Bayer AG (Germany) Description, Business Overview and Total Revenue
6.5.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Bayer AG (Germany) Products Offered
6.5.5 Bayer AG (Germany) Recent Development
6.6 Bracco Imaging S.p.A (Italy)
6.6.1 Bracco Imaging S.p.A (Italy) Corporation Information
6.6.2 Bracco Imaging S.p.A (Italy) Description, Business Overview and Total Revenue
6.6.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Bracco Imaging S.p.A (Italy) Products Offered
6.6.5 Bracco Imaging S.p.A (Italy) Recent Development
6.7 Eczacibasi-Monrol Nuclear Products (Turkey)
6.6.1 Eczacibasi-Monrol Nuclear Products (Turkey) Corporation Information
6.6.2 Eczacibasi-Monrol Nuclear Products (Turkey) Description, Business Overview and Total Revenue
6.6.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Eczacibasi-Monrol Nuclear Products (Turkey) Products Offered
6.7.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Development
6.8 Nordion, Inc. (Canada)
6.8.1 Nordion, Inc. (Canada) Corporation Information
6.8.2 Nordion, Inc. (Canada) Description, Business Overview and Total Revenue
6.8.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Nordion, Inc. (Canada) Products Offered
6.8.5 Nordion, Inc. (Canada) Recent Development
6.9 Advanced Accelerator Applications S.A. (France)
6.9.1 Advanced Accelerator Applications S.A. (France) Corporation Information
6.9.2 Advanced Accelerator Applications S.A. (France) Description, Business Overview and Total Revenue
6.9.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Advanced Accelerator Applications S.A. (France) Products Offered
6.9.5 Advanced Accelerator Applications S.A. (France) Recent Development
6.10 IBA Molecular Imaging (Belgium)
6.10.1 IBA Molecular Imaging (Belgium) Corporation Information
6.10.2 IBA Molecular Imaging (Belgium) Description, Business Overview and Total Revenue
6.10.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
6.10.4 IBA Molecular Imaging (Belgium) Products Offered
6.10.5 IBA Molecular Imaging (Belgium) Recent Development

7 PET Radiopharmaceuticals Manufacturing Cost Analysis
7.1 PET Radiopharmaceuticals Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of PET Radiopharmaceuticals
7.4 PET Radiopharmaceuticals Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 PET Radiopharmaceuticals Distributors List
8.3 PET Radiopharmaceuticals Customers

9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis

10 Global Market Forecast
10.1 Global PET Radiopharmaceuticals Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of PET Radiopharmaceuticals by Type (2021-2026)
10.1.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Type (2021-2026)
10.2 PET Radiopharmaceuticals Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of PET Radiopharmaceuticals by Application (2021-2026)
10.2.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Application (2021-2026)
10.3 PET Radiopharmaceuticals Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of PET Radiopharmaceuticals by Region (2021-2026)
10.3.2 Global Forecasted Revenue of PET Radiopharmaceuticals by Region (2021-2026)
10.4 North America PET Radiopharmaceuticals Estimates and Projections (2021-2026)
10.5 Europe PET Radiopharmaceuticals Estimates and Projections (2021-2026)
10.6 Asia Pacific PET Radiopharmaceuticals Estimates and Projections (2021-2026)
10.7 Latin America PET Radiopharmaceuticals Estimates and Projections (2021-2026)
10.8 Middle East and Africa PET Radiopharmaceuticals Estimates and Projections (2021-2026)
11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample